Dicerna to Present New GalXC-Plus™ Nonclinical CNS Data at Oligonucleotide and Precision Therapeutics Virtual Congress
Mar 24, 2021
The keynote presentation titled, “GalXC-Plus: Cell-Type Targeted Therapeutic Oligonucleotide Delivery in the CNS,” will take place on
The presentation will be made available on the Events & Presentations page of Dicerna’s corporate website following the presentation.
About Dicerna's GalXC™ RNAi Technology Platform
Dicerna’s proprietary GalXC™ RNA interference (RNAi) platform aims to advance the development of next-generation RNAi-based therapies designed to silence genes implicated in disease. Investigational therapeutics developed using our flagship GalXC technology utilize a proprietary N-acetyl-D-galactosamine (GalNAc)-mediated structure of double-stranded RNA molecules that are designed to bind specifically to receptors on liver cells, leading to selective hepatocyte internalization and access to the RNAi machinery within the cells. Dicerna is continuously innovating and exploring new applications for RNAi technology beyond GalNAc-mediated delivery to the liver, including alternative RNA structures and fully synthetic ligands that target other tissues and enable new therapeutic applications, referred to as GalXC-Plus™.
Cautionary Note on Forward-Looking Statements
This press release includes forward-looking statements pertaining to the Company’s planned participation in the
GalXC™ and GalXC-Plus™ are trademarks of